A huge percentage of the increase in health spending is caused by very expensive drugs administered in a provider's office.
Read More
A National Bureau of Economic Research paper confirms earlier research on the effect of drug rebates on net prices to drug makers.
Read More
MedPAC's annual report to Congress includes examination of the effects of hospital consolidation and abuses of the 340B program.
Read More
A study in JAMA reveals once again the avaricious pricing behavior of drug companies.
Read More
A study in JAMA discusses the profitability of large drug companies.
Read More
Giving doctors more information about a patient's adherence to prescriptions and access to pharmacist help did not improve adherence to medication regimens.
Read More
Drug manufacturer payments to doctors appear to have modest effects on prescribing behavior.
Read More
Express Scripts gives us its version of 2019 prescription drug spending and utilization trends.
Read More
A study in JAMA Internal Medicine describes trends in drug manufacturer detailing of physicians.
Read More
A paper from EBRI discusses differences in cost for the same cancer medication in different sites of service.
Read More
A Statistical Brief from AHRQ examines certain trends in costs of retail drugs.
Read More
A new study relating to hospitals participation in the 340B program finds that they are making excellent profits, which was not the intention.
Read More
The Government Accounting Office releases a report on the role of pharmacy benefit managers in Medicare Part D.
Read More
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.
Apple Podcasts
Google Podcasts
Spotify
Overcast
PocketCasts
Radio Public
Stitcher
Anchor
RSS - Posts